Brown, Lisle/Cummings’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Brown, Lisle/Cummings’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Hold	2,196	–	–	0.05%	226
2026 Q1	$190K	Sell	2,196 -180	-8%	-$15.8K	0.05%	217
2025 Q4	$202K	Hold	2,376	–	–	0.05%	207
2025 Q3	$172K	Hold	2,376	–	–	0.04%	223
2025 Q2	$156K	Buy	2,376 +129	+6%	+$8.4K	0.04%	235
2025 Q1	$159K	Hold	2,247	–	–	0.05%	227
2024 Q4	$148K	Hold	2,247	–	–	0.04%	232
2024 Q3	$159K	Sell	2,247 -858	-28%	-$59.8K	0.05%	228
2024 Q2	$206K	Hold	3,105	–	–	0.07%	196
2024 Q1	$211K	Hold	3,105	–	–	0.07%	189
2023 Q4	$192K	Sell	3,105 -63	-2%	-$3.7K	0.07%	198
2023 Q3	$187K	Hold	3,168	–	–	0.08%	189
2023 Q2	$189K	Hold	3,168	–	–	0.08%	184
2023 Q1	$185K	Hold	3,168	–	–	0.09%	176
2022 Q4	$197K	Sell	3,168 -264	-8%	-$15.9K	0.11%	159
2022 Q3	$194K	Hold	3,432	–	–	0.11%	149
2022 Q2	$219K	Sell	3,432 -825	-19%	-$52.4K	0.12%	150
2022 Q1	$276K	Buy	4,257 +192	+5%	+$12.2K	0.13%	145
2021 Q4	$270K	Buy	+4,065	New	+$258K	0.14%	142

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Brown, Lisle/Cummings's IHE Position: Q2 2026 in Review

Brown, Lisle/Cummings held its iShares US Pharmaceuticals ETF (IHE) position steady in Q2 2026 at 2,196 shares worth $217K. The position accounts for 0.05% of the portfolio, ranked #226.

Brown, Lisle/Cummings first reported a position in IHE in Q4 2021 and has held it in 19 quarters since. The position peaked at $276K in Q1 2022. 210 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Brown, Lisle/Cummings held 2,196 shares of iShares US Pharmaceuticals ETF worth $217K as of Q2 2026.
Brown, Lisle/Cummings left its iShares US Pharmaceuticals ETF share count unchanged in Q2 2026.
iShares US Pharmaceuticals ETF made up 0.05% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #226 holding.
Brown, Lisle/Cummings first reported a position in iShares US Pharmaceuticals ETF in Q4 2021 and has held it in 19 quarters since.
Brown, Lisle/Cummings's iShares US Pharmaceuticals ETF position peaked at $276K in Q1 2022.
210 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.